Many intracellular oligonucleotide studies begin with a clear biological objective: a target RNA, a validated antisense sequence, a splice-switching oligo, or a model nucleic acid cargo. The harder question is often how to get that cargo into cells in a form that remains available for the intended mechanism. Cell-penetrating peptide-oligonucleotide conjugates are one research strategy for addressing this delivery challenge, but their performance depends on more than simply attaching a positively charged peptide to an oligonucleotide. Peptide sequence, charge distribution, linker chemistry, conjugation site, oligonucleotide chemistry, solubility, purification behavior, and analytical confirmation all influence whether a project is technically feasible.
For RNA therapeutics researchers, antisense teams, molecular biology laboratories, and procurement managers, the key decision is not only whether a CPP-oligonucleotide conjugate can be made. It is whether the selected design is suitable for the intended assay, compatible with the oligonucleotide chemistry, realistic to purify, and supported by appropriate quality control. This guide explains the core design principles used when planning CPP-oligonucleotide conjugates for intracellular delivery research.
A cell-penetrating peptide-oligonucleotide conjugate is a covalent construct that combines a cell-penetrating peptide, often abbreviated as CPP, with an oligonucleotide cargo. The peptide portion is intended to support cellular association, internalization, or intracellular delivery, while the oligonucleotide portion provides the sequence-specific biological function. The two components are connected through a defined linker or chemical bond, usually at the peptide terminus, an amino acid side chain, or the 5' or 3' end of the oligonucleotide.
In delivery research, CPP-oligonucleotide conjugates are used to evaluate whether a peptide can improve uptake or functional activity of a nucleic acid cargo in a specific cell model. These conjugates may be designed as simple binary structures containing one peptide and one oligonucleotide, or as more complex constructs that include spacers, cleavable linkers, fluorescent labels, endosomal escape motifs, or additional functional groups. The best design depends on the cargo type, assay readout, cell model, and tolerance for changes to either the peptide or oligonucleotide structure.
CPPs are short peptide sequences that are commonly rich in cationic, amphipathic, or membrane-interacting residues. Arginine-rich sequences, lysine-containing sequences, amphipathic helices, and peptide motifs derived from natural proteins have all been studied as delivery vectors. Their role is not identical in every conjugate. Some CPPs mainly increase association with the cell surface. Others support internalization through endocytic pathways. Some designs also attempt to improve endosomal escape, although this remains a major limiting step in many delivery systems.
The charge and hydrophobicity of the CPP strongly affect conjugate behavior. A highly cationic peptide may interact efficiently with negatively charged cell-surface components and negatively charged oligonucleotides, but it may also increase aggregation, nonspecific binding, cytotoxicity risk, or purification difficulty. A more amphipathic sequence may support membrane interaction, but hydrophobic residues can reduce solubility. For this reason, CPP selection should be treated as a design variable rather than a universal solution.
CPPs can be conjugated to several oligonucleotide-related cargo types, but each cargo introduces different chemical and analytical constraints. Standard phosphodiester DNA or RNA sequences are generally more susceptible to nuclease degradation and are less common for serious delivery studies unless used as model substrates. Modified antisense oligonucleotides may include phosphorothioate backbones, 2'-O-modifications, locked nucleic acid residues, or other stabilizing modifications. Charge-neutral analogs such as PMO and PNA behave differently from negatively charged nucleic acids and may be more compatible with certain CPP designs because they reduce electrostatic complexation between the peptide and cargo.
Splice-switching oligonucleotides are often used as functional readouts because activity can be measured by changes in splicing pattern. PNA and PMO cargoes are also used in steric-blocking applications where the oligonucleotide binds a target sequence without recruiting RNase H. For siRNA-related applications, the design question is more complex because duplex formation, strand orientation, and RNA-induced silencing complex compatibility must be considered. In many research programs, single-strand conjugates are evaluated first because they are easier to define and characterize.
| Cargo Type | Typical Application | CPP Design Consideration | QC Concern |
| ASO | RNase H-mediated knockdown, steric blocking, target validation | Backbone charge and chemical modifications may affect solubility and peptide interaction | Confirmation of correct mass, conjugation efficiency, and separation from unconjugated ASO |
| PMO | Splice switching, translation blocking, exon-skipping research | Charge-neutral backbone can reduce electrostatic aggregation with cationic CPPs | Purification of full conjugate from free CPP, free PMO, and truncated species |
| PNA | Steric blocking, antisense research, hybridization-based inhibition | Peptide-like backbone may allow integrated peptide-PNA synthesis strategies | Hydrophobicity, aggregation, and closely related synthesis impurities |
| siRNA-related strand | RNA interference model studies, delivery comparison, strand-specific uptake analysis | Attachment site must avoid disrupting duplex formation and functional strand loading | Duplex integrity, strand identity, conjugation site, and residual unconjugated strand |
| Splice-switching oligo | Reporter assays, exon inclusion or exclusion studies, cellular activity screening | Linker and CPP should preserve nuclear availability after uptake | Functional activity can be limited by endosomal entrapment despite correct synthesis |
Table 1 Common Oligonucleotide Cargo Types for CPP Conjugation
Oligonucleotides are powerful research tools because they can be designed to recognize nucleic acid targets with high sequence specificity. However, their size, charge, polarity, and susceptibility to biological barriers make intracellular delivery difficult. CPP conjugation is used to explore whether a defined peptide can improve cellular uptake, intracellular trafficking, or functional availability of the oligonucleotide cargo. Unlike noncovalent formulation approaches, a covalent conjugate gives a defined molecular entity, which can simplify structure-activity comparison when the conjugate is properly purified and characterized.
Many oligonucleotides do not readily cross the plasma membrane on their own. Negatively charged backbones interact strongly with water and counterions, which limits passive diffusion through lipid bilayers. Even when chemical modifications improve nuclease resistance or protein binding, they do not automatically solve intracellular delivery. Cell type, culture conditions, oligonucleotide chemistry, concentration, and assay duration can all influence apparent activity.
CPP conjugation can increase cell association and internalization, but uptake should be interpreted carefully. Fluorescence signal inside or near cells does not always prove that the oligonucleotide reached the cytosol or nucleus in an active form. For this reason, delivery studies should include functional assays, matched controls, and where possible, orthogonal localization or uptake measurements.
A major challenge for CPP-oligonucleotide conjugates is endosomal entrapment. Many CPP conjugates enter cells through endocytic pathways. After internalization, a large fraction of the material may remain in endosomes or lysosomal compartments. If the oligonucleotide target is in the cytosol or nucleus, endosomal retention can limit activity even when total cellular uptake appears high.
Endosomal escape is therefore a key feasibility question. Some CPPs are selected for membrane-disruptive or endosomolytic properties, while other designs include additional functional motifs or cleavable linkers. However, increasing membrane activity can also increase cytotoxicity or nonspecific effects. The goal is not maximum uptake at any cost, but useful intracellular availability with acceptable cell compatibility and interpretable assay results.
Research-use CPP-oligonucleotide conjugates are typically designed to answer mechanistic, screening, or feasibility questions. The priorities may include rapid synthesis, clear mass confirmation, sufficient purity for cell assays, and availability of matched controls. Therapeutic development introduces additional requirements, including in vivo stability, tissue distribution, pharmacokinetics, immunogenicity assessment, toxicology, scalable manufacturing, and regulatory documentation.
A conjugate that is suitable for an in vitro reporter assay may not be suitable for animal studies or therapeutic development. Conversely, a highly optimized therapeutic-style design may be unnecessarily complex for early discovery. Defining the intended use at the beginning helps determine scale, purity target, analytical package, linker selection, and whether additional control compounds should be synthesized.
A CPP-oligonucleotide conjugate should be designed as a complete molecular system. The peptide, cargo, linker, attachment site, and purification strategy must be compatible with one another. A strong CPP candidate can fail if the oligonucleotide modification is incompatible with the conjugation chemistry. A well-designed linker can still perform poorly if the conjugate aggregates or cannot be separated from unconjugated starting materials. Early feasibility review helps identify these risks before synthesis begins.
| Design Factor | Key Question | Technical Risk | Design Recommendation |
| CPP sequence | Is the peptide cationic, amphipathic, hydrophobic, or sequence-specific? | Aggregation, nonspecific binding, cytotoxicity, or low uptake | Compare charge, hydrophobicity, length, and known assay context before selection |
| Oligonucleotide chemistry | Is the cargo negatively charged, charge-neutral, modified, duplexed, or steric-blocking? | Incompatibility with conjugation, purification, or functional mechanism | Confirm terminal modifications and biological mechanism before choosing chemistry |
| Linker type | Should the bond be stable, cleavable, flexible, or trackable? | Premature cleavage, poor release, steric hindrance, or difficult analysis | Match linker stability to assay conditions and desired intracellular behavior |
| Attachment site | Should the CPP be attached at the 5' end, 3' end, internal site, peptide N-terminus, C-terminus, or side chain? | Loss of hybridization, impaired strand loading, blocked peptide activity | Select a site that preserves both oligonucleotide function and CPP properties |
| Purification | Can the conjugate be separated from free peptide, free oligo, and side products? | Co-elution, broad peaks, adsorption, low recovery | Plan analytical and preparative methods before committing to final scale |
Table 2 CPP-Oligonucleotide Design Factors
CPP sequence selection is one of the most important design decisions. Arginine-rich peptides often provide strong interactions with cell surfaces and nucleic acid-related structures, but they may also create purification and solubility challenges. Lysine-rich sequences may be easier to synthesize in some contexts but can introduce reactive side chains that must be considered during functionalization. Amphipathic peptides can support membrane interaction, but hydrophobic segments may cause aggregation or poor aqueous handling.
The number and placement of charged residues matter. A peptide with clustered positive charges may behave differently from one with distributed charge. Cysteine, lysine, azide-bearing residues, alkyne-bearing residues, or other functional handles can be incorporated to enable site-specific conjugation. However, adding a functional handle can change peptide behavior, especially if the peptide is short. For difficult CPPs, it is useful to evaluate predicted solubility, isoelectric point, hydrophobic residues, oxidation-sensitive residues, and possible intramolecular or intermolecular interactions before synthesis.
Oligonucleotide chemistry determines both biological mechanism and conjugation compatibility. Phosphorothioate ASOs may have improved nuclease resistance compared with unmodified phosphodiester sequences, but their sulfur-containing backbone can affect metal sensitivity and chromatographic behavior. 2'-modified RNA-like residues can influence affinity and stability. PMO and PNA cargoes are charge-neutral and may avoid some electrostatic interactions, but they introduce their own synthetic and analytical considerations.
The position of functional groups should be confirmed early. A 5'-amine, 3'-thiol, 5'-azide, alkyne-modified residue, or internal modified base may each support different conjugation routes. Some oligonucleotide modifications are sensitive to strongly acidic, strongly basic, oxidative, reductive, or metal-catalyzed conditions. For duplex-related applications, the conjugation site must also avoid disrupting hybridization or the intended biological processing pathway.
The linker connects the CPP and oligonucleotide, but it is not merely a passive bridge. Linker length, flexibility, hydrophilicity, and cleavage behavior can affect solubility, steric accessibility, hybridization, uptake, and intracellular activity. Short linkers may create a compact molecule but can restrict movement between the peptide and cargo. Longer spacers can reduce steric interference, but they may increase molecular weight and introduce additional synthetic complexity.
Stable linkers are often preferred when the goal is to evaluate a defined conjugate throughout an uptake or activity assay. Cleavable linkers may be considered when release of the oligonucleotide is desired after internalization. Disulfide linkers are commonly discussed because the intracellular environment can be more reducing than extracellular conditions, but reduction is not guaranteed in every compartment. Linker selection should be based on the intended biological hypothesis rather than chosen only because a chemistry is convenient.
The attachment site determines the orientation of the conjugate. For many oligonucleotides, 5' or 3' terminal attachment is preferred because it is synthetically accessible and less likely to interfere with base pairing than internal modification. However, the best terminus depends on the oligonucleotide mechanism. An RNase H gapmer, splice-switching oligo, PMO, PNA, or siRNA-related strand may each have different tolerance for terminal conjugation.
Peptide orientation also matters. N-terminal conjugation, C-terminal conjugation, and side-chain conjugation can produce molecules with different charge presentation and biological behavior. If the CPP requires a free N-terminus, C-terminal or side-chain attachment may be preferred. If the peptide contains lysines, cysteine, or other reactive residues, orthogonal protection or selective functionalization may be needed to avoid heterogeneous products. Orientation should be chosen to preserve the delivery function of the CPP and the target-binding function of the oligonucleotide.
CPP-oligonucleotide conjugates can be prepared by several strategies. Some constructs are assembled through stepwise solid-phase approaches, while many are prepared by post-synthetic conjugation of separately synthesized and functionalized peptide and oligonucleotide fragments. Post-synthetic conjugation is often attractive because each fragment can be purified and characterized before coupling, but it may also introduce yield loss, solubility problems, and an additional purification challenge after conjugation.
Thiol-maleimide conjugation is widely used in bioconjugation because it can connect a thiol-bearing component with a maleimide-bearing component under relatively mild conditions. In a CPP-oligonucleotide project, the thiol may come from a cysteine-containing peptide or a thiol-modified oligonucleotide. The maleimide group can be introduced onto the complementary fragment through an appropriate activated reagent or modifier.
This strategy is useful when site-specific conjugation is desired, but the design must account for side reactions and stability. Free thiols can oxidize to disulfides, and maleimide groups can undergo hydrolysis or react with unintended nucleophiles. If a peptide contains lysine residues or other potentially reactive side chains, the placement and timing of maleimide introduction should be carefully considered. For some projects, it may be preferable to introduce the maleimide on the oligonucleotide rather than store a maleimide-bearing lysine-rich CPP for extended periods.
Azide-alkyne click chemistry is another common approach for preparing peptide-oligonucleotide conjugates. One fragment is functionalized with an azide and the other with an alkyne. The reaction can provide chemoselective ligation and is compatible with many functional groups. Peptides can often be modified with azido or alkynyl amino acid derivatives during solid-phase peptide synthesis, while oligonucleotides can be prepared with terminal or internal click handles using suitable modifiers.
The design team should determine whether copper-catalyzed or copper-free chemistry is appropriate. Copper-catalyzed reactions can be efficient, but copper exposure may be undesirable for certain oligonucleotide chemistries or biological applications unless conditions are controlled and purification is robust. Copper-free strain-promoted click reactions avoid copper but require bulkier strained alkyne reagents, which may affect linker size, hydrophobicity, and cost.
Amide bond formation can produce a stable linkage between an amine and an activated carboxyl group. In peptide chemistry, amide bonds are familiar and robust. For CPP-oligonucleotide conjugates, amide coupling may be used when one component carries an amino group and the other carries a carboxyl or activated ester. This approach can be useful for terminal attachment or for linker-mediated conjugation.
The main challenge is selectivity. Peptides may contain multiple amines, including the N-terminus and lysine side chains. Without proper protection or site-specific design, amide coupling can produce heterogeneous products. Oligonucleotide solubility, buffer composition, pH, and reagent compatibility must also be considered. Amide coupling is most attractive when the reactive groups are unique and accessible.
Disulfide linkers are used when a reducible connection between CPP and oligonucleotide is desired. The concept is straightforward: the conjugate remains linked during handling and uptake, then the disulfide may be reduced in intracellular environments, releasing or altering the cargo. In practice, disulfide behavior depends on the cellular compartment, cell type, exposure time, and accessibility of the bond.
Disulfide formation can be performed through direct oxidation of two thiol-containing components or through activated disulfide intermediates. Direct oxidation may generate homodimers or mixed products if not controlled. Activated disulfide strategies can improve selectivity but require compatible functional groups and purification. Other cleavable linkers, including enzyme-sensitive or acid-sensitive linkers, may be considered for specialized designs, but they should be matched to a clear delivery hypothesis and validated with appropriate controls.
Analytical planning is essential for CPP-oligonucleotide conjugates because these molecules combine two classes of compounds with very different physicochemical properties. Peptides may be hydrophobic, cationic, oxidation-sensitive, or aggregation-prone. Oligonucleotides may be highly charged, sequence-dependent, metal-sensitive, or difficult to ionize consistently. After conjugation, the resulting molecule may show broad chromatographic peaks, strong adsorption, unusual retention behavior, or multiple charge states in mass spectrometry.
Purity requirements should reflect the intended experiment. Early screening materials may not require the same purity as advanced in vivo research materials, but the conjugate should be sufficiently pure to support interpretable results. Unconjugated CPP can cause nonspecific cellular effects. Unconjugated oligonucleotide can confound activity measurements. Partially deprotected, truncated, oxidized, or aggregated species may affect uptake, toxicity, or assay background.
Preparative HPLC is commonly used, but method development may be needed. A conjugate with both cationic peptide and anionic oligonucleotide domains may behave differently from either starting material. In some cases, ion-pairing reversed-phase methods, ion-exchange methods, desalting, or orthogonal analytical approaches may be required. The feasibility of purification should be considered before selecting a highly hydrophobic CPP, very long oligonucleotide, or complex multifunctional linker.
Mass confirmation verifies that the observed molecular weight is consistent with the designed conjugate. This is especially important when the construct contains modified bases, terminal functional groups, non-natural amino acids, cleavable linkers, labels, or charge-neutral backbones. Mass spectrometry can help distinguish the desired conjugate from unconjugated fragments and certain side products.
However, mass confirmation should not be interpreted as a complete purity assessment by itself. A correct mass peak does not rule out closely related impurities, truncated products, salts, counterions, aggregates, or co-eluting species. For delivery research, mass data should be evaluated alongside chromatographic purity, synthesis records, and functional assay controls.
Large or highly charged CPP-oligonucleotide conjugates can be analytically challenging. Arginine-rich peptides may interact strongly with oligonucleotides and chromatographic surfaces. Phosphorothioate oligonucleotides can create complex peak patterns because of stereochemical and chemical heterogeneity. PMO and PNA conjugates may require different analytical handling from standard DNA or RNA oligonucleotides. Fluorescent labels or hydrophobic spacers can further alter retention and recovery.
These limitations do not mean that the conjugate cannot be made. They mean that feasibility review should include realistic expectations for purity, yield, analytical resolution, and reporting. For difficult constructs, it may be useful to prepare a small pilot scale first, compare alternative linker placements, or synthesize matched unconjugated controls to support interpretation.
Custom support is valuable when a project involves more than a straightforward peptide and a standard terminally modified oligonucleotide. The earlier the design is reviewed, the easier it is to avoid incompatible functional groups, poor attachment sites, difficult purification profiles, and missing controls. A feasibility review can also help determine whether the requested scale and purity are realistic for the selected construct.
Complex CPP sequences may contain multiple arginines, lysines, cysteine residues, hydrophobic segments, D-amino acids, non-natural amino acids, cyclization motifs, or terminal modifications. These features can improve biological performance in some settings, but they can also complicate synthesis and conjugation. For example, a cysteine may be needed as a conjugation handle, but additional cysteines can create disulfide scrambling. Multiple lysines can improve charge but introduce selectivity concerns if amide coupling or maleimide chemistry is not carefully designed.
Sequence review should assess synthesis difficulty, side-chain protection, solubility, oxidation risk, and compatibility with the intended oligonucleotide cargo. If the CPP has not been used with the selected cargo type before, a pilot conjugation may be more appropriate than moving directly to a large scale.
Modified oligonucleotides require careful review because terminal handles, backbone chemistry, sugar modifications, base modifications, and protecting group history can affect conjugation. A 5'-amine ASO, 3'-thiol PMO, azide-modified PNA, internally modified oligo, or duplex-forming strand may each require a different strategy. If the oligonucleotide is supplied by the customer, documentation of sequence, chemistry, molecular weight, purification grade, salt form, and functional handle is important.
The attachment site should be selected with the biological mechanism in mind. For splice-switching oligos, the conjugate must preserve target binding and nuclear activity. For siRNA-related strands, the design must consider duplexing and strand function. For steric-blocking ASO, PMO, or PNA cargoes, terminal conjugation may be acceptable, but it should still be checked against the target-binding region and assay design.
Purification becomes difficult when the conjugate, free peptide, and free oligonucleotide have similar chromatographic behavior or when the conjugate binds strongly to surfaces. Highly cationic CPPs, long oligonucleotides, hydrophobic labels, and amphipathic sequences can all reduce recovery. If the desired conjugate co-elutes with free CPP or free oligo, additional method development may be required.
Purification planning should include the expected impurities. These may include unconjugated peptide, unconjugated oligonucleotide, peptide dimers, oligonucleotide truncations, hydrolyzed linker products, oxidized peptide species, and partially conjugated materials in multifunctional designs. A realistic specification should define the target purity, analytical method, acceptable counterion or salt form, and reporting format.
Matched controls are essential for interpreting CPP-oligonucleotide delivery experiments. A study may require unconjugated oligonucleotide, unconjugated CPP, scrambled oligonucleotide conjugate, inactive sequence conjugate, linker-only oligonucleotide, fluorescent conjugate, or a non-cleavable analog of a cleavable design. Without controls, it may be difficult to determine whether observed activity comes from sequence-specific oligonucleotide action, peptide-driven cytotoxicity, nonspecific uptake, or assay interference.
Controls should be planned at the same time as the main conjugate because they may require related functional handles, linker designs, and purification methods. Ordering controls later can delay a project or introduce batch-to-batch differences that complicate comparison.
Creative Peptides supports research teams that need technically reviewed CPP-oligonucleotide conjugates for intracellular delivery studies. Project support may include custom CPP synthesis, incorporation of functional handles, peptide solubility review, peptide-oligonucleotide conjugation planning, purification strategy development, and characterization of research-use conjugates. The goal is to help researchers move from a target sequence and delivery concept to a feasible molecular design that can be synthesized, purified, and evaluated in the intended assay.
A successful project discussion usually begins with the peptide sequence, oligonucleotide type, desired attachment site, preferred linker, required scale, target purity, and intended biological readout. If the design is still open, Creative Peptides can help compare options such as N-terminal versus C-terminal CPP attachment, stable versus cleavable linker, thiol-maleimide versus click chemistry, and whether matched controls should be prepared in parallel.
Because CPP-oligonucleotide conjugates vary widely in synthesis and purification difficulty, feasibility review is especially important for modified oligonucleotides, highly charged CPPs, long sequences, hydrophobic labels, and multifunctional constructs. Early review helps identify technical risks before materials are ordered and supports a more efficient path toward interpretable delivery data.
To request a feasibility review for a CPP-oligonucleotide conjugate, provide as much structural and experimental information as possible. Useful details include the CPP sequence, peptide termini, any non-natural amino acids, oligonucleotide sequence or length, oligonucleotide chemistry, terminal or internal functional handles, desired attachment site, linker preference, target scale, purity requirement, and intended assay. If the cargo is a PMO, PNA, ASO, siRNA-related strand, or splice-switching oligo, specify the cargo type clearly because each has different design and analytical considerations.
Researchers are also encouraged to describe the cell model, delivery endpoint, planned concentration range, and required controls. These details help determine whether the proposed conjugate is appropriate for uptake imaging, splice correction, knockdown, steric blocking, reporter assays, or other intracellular delivery studies. For complex constructs, a pilot synthesis or alternative design may be recommended before committing to larger-scale preparation.
Submit your peptide sequence, oligonucleotide type, desired attachment site, linker preference, scale, purity requirement, and intended assay to Creative Peptides for custom CPP-oligonucleotide conjugation feasibility review and quotation.
A CPP-oligonucleotide conjugate is a covalent construct that links a cell-penetrating peptide to an oligonucleotide cargo. The CPP is used to support cellular association or uptake, while the oligonucleotide provides sequence-specific biological function.
Common research cargoes include ASOs, PMOs, PNAs, siRNA-related strands, and splice-switching oligonucleotides. Feasibility depends on cargo chemistry, functional handles, attachment site, linker compatibility, and purification behavior.
No. CPP conjugation may improve uptake or cell association, but intracellular activity can still be limited by endosomal entrapment, poor release, cytotoxicity, inappropriate attachment site, or loss of oligonucleotide function. Functional controls are required.
There is no universal best site. Many designs use 5' or 3' oligonucleotide attachment and N-terminal, C-terminal, or side-chain peptide attachment. The best site depends on oligonucleotide mechanism, peptide function, linker chemistry, and assay requirements.
Provide the CPP sequence, oligonucleotide type and chemistry, desired attachment site, linker preference, scale, purity requirement, functional handles, intended assay, and any required controls or labels.
